Purpose: Radical cystectomy currently remains the standard of care for muscle-invasive bladder cancer. However, surgery can be associated with considerable morbidity and mortality, including the removal of the bladder. An alternative strategy is to preserve the bladder through concurrent chemoradiation following a maximal transurethral resection of the tumor. National protocols using a bladder-preservation approach have demonstrated disease-specific outcomes comparable to radical cystectomy in selected patients, but these results have not been replicated in previously reported population-based series. Here, we describe an outcomes analysis of patients with muscle-invasive bladder cancer treated with either radical surgery or bladder-preserving chemoradiation (BPCRT) for those patients meeting BPCRT criterion using the National Cancer Database (NCDB).
B
ladder cancer remains a significant clinical challenge, with over 75,000 new cases diagnosed annually. 1 The treatment of patients with muscle-invasive bladder cancers (MIBCs), disease that has invaded the muscularis propria, has traditionally been managed through radical cystectomy. 2 Radical surgery, however, is accompanied by significant treatment morbidity and mortality, including the removal of the natural bladder. 3 Combined modality bladder preservation has emerged as a viable oncologic paradigm, which may allow the preservation of the natural bladder through concurrent chemotherapy and radiation after aggressive transurethral tumor resection in select patients. [4] [5] [6] [7] Similar approaches for organ preservation using definitive chemoradiation in lieu of radical resection have been adopted for selected stages in other disease sites such as cancers of the oropharynx, larynx, and anal canal.
Over the past 3 decades, the Radiation Therapy Oncology Group and British Columbia Cooperative Groups have conducted several multicenter studies examining the outcomes of bladder preservation with chemoradiotherapy (CRT). [8] [9] [10] [11] [12] [13] Recent reports of pooled analysis with 10-year outcomes in these patients demonstrated comparable survival outcomes to those of radical surgery. 2, 5, 6 In addition, the rate of bladder-intact disease-free survival has been reported to be 50% to 60% at 10 years. Despite these promising reports, bladder-preserving strategies through the use of concurrent chemoradiation have not been adopted as a standard therapy.
These previously reported series investigating bladderpreserving chemoradiation (BPCRT) represent carefully selected patients treated within strict trial protocols. Thus, the outcomes of these clinical protocols may differ from those achieved in routine clinical practice. Here we utilize the National Cancer Database (NCDB) to directly compare the outcomes of patients with MIBC treated with radical cystectomy with BPCRT in a real-world practice setting.
MATERIALS AND METHODS

Patient Cohorts
The NCDB registry was used to identify study subjects. The NCDB is a national clinical oncology database sourced from hospital registry data collected from over 1500 Commission on Cancer-accredited facilities and captures at least 70% of new cancer cases in the United States. 14, 15 The NCDB contains valuable information not available in other national registries, including detailed radiotherapy information. Data are reported retrospectively to the NCDB and contains no patient or physician identifiers and is consequently exempt from the (blinded) Institutional Review Board.
Patients with a first and only diagnosis of pathologically confirmed urothelial carcinoma were queried from the NCDB. Patients with American Joint Commission on Cancer clinically staged T-stage 2 and 3, N-stage 0, and M-stage 0 were included for analysis, as these patients would have qualified for previous national bladder-preservation studies. 6, 8, 10, 12 Patients documented to have undergone radical cystectomy or anterior exenteration was included in the surgery cohort. Patients who underwent radiation for initial treatment were excluded from the surgery cohort. Only patients documented to have received a transurethral tumor resection (TURBT) and external beam irradiation to the pelvis and/or bladder with > 25 total radiation fractions with single or multiagent chemotherapy were included in the BPCRT cohort. Patients receiving palliative surgery or radiation were excluded.
Statistical Analyses
Descriptive statistics were compiled to summarize the patient demographics, disease, and treatment characteristics. Association of the baseline characteristics with treatment group was assessed using χ 2 tests or analysis of variance, where appropriate. For the surgery cohort, overall survival (OS) was calculated from first treatment date (either definitive surgery or receipt of chemotherapy) to date of death or last follow-up. For the BPCRT cohort, OS was calculated from first treatment date (either receipt of chemotherapy or radiation therapy) to date of death or last follow-up. As such, if a patient received neoadjuvant chemotherapy, his/her survival is calculated from the start of the neoadjuvant chemotherapy for both cohorts. Univariate association of patient, tumor, and treatment factors with OS was evaluated using log-rank tests, and OS were estimated using the Kaplan-Meier method. Yearly Kaplan-Meier rates between treatment groups also were compared using Z tests. Univariate and multivariable (MV) Cox proportional hazards (PHs) models were fit for OS as a function of patient demographics, disease, and treatment characteristics. In the MV model, the presence of multicollinearity was checked via variance inflation factors. The PHs assumption was also checked. In cases where the PH assumption was violated, and an interaction was fit between the covariate and OS, and a time-varying hazard ratio (HR) was reported. Statistical analyses were performed using SAS, version 9.3 (Cary, NC), and SAS macros or software developed at the Biostatistics and Bioinformatics Shared Core Resource at Emory University. 16 Propensity-score analysis was also performed to reduce treatment selection bias, utilizing the propensity-score matching method. Covariates used for propensity matching are ones calculated to significantly affect OS on MV analysis and included: patient age, facility type, Charlson-Deyo comorbidity score, disease site, and American Joint Commission on Cancer T-stage. Patients from each cohort were matched at a ratio of 1:1 based on the propensity score using a 5-1 digit match algorithm. The balance of the propensity matching between cohorts was assessed by their standardized differences, with a value of <0.1 to be considered a negligible difference. 17 
RESULTS
Between 2004 and 2013, there were 439,188 cases of bladder cancer in the NCDB queried for this study. Of these patients, 7276 and 1178 patients met our criteria for definitive treatment with radical cystectomy and BPCRT, respectively ( Fig. 1) . The time from diagnosis to the first day of treatment was similar for both cohorts, with a median of 1.5 months (25th to 75th percentile: 0.9 to 2.3 mo) and 1.5 months (25th-75th percentile: 1.0-2.4 mo), for the BPCRT and surgery cohorts, respectively. At baseline, there were significant differences between the groups in several patient and tumor characteristics (Table 1) . Patients who were treated with BPCRT were older (median age: 75 for BPCRT vs. 67 for surgery), had more medical comorbidities (Charlson-Deyo Score 0: 65.6% for BPCRT vs. 69.5% for surgery), and lived closer to their treatment center (median miles: 7.5 BPCRT for and 16.4 for surgery), all P-value <0.001. Patients treated with BPCRT had a slightly lower proportion of clinically staged T3 tumors (11.3% for BPCRT and 13.5% for surgery, P = 0.036). The primary site of disease in the bladder also differed between the 2 cohorts (P < 0.001). Kaplan-Meier curves for the 2 cohorts are displayed in Figure 2A , demonstrating median OS of 2.6 and 3.8 years for the BPCRT and surgery cohorts, respectively (P < 0.001).
On MV analysis, advanced age at diagnosis, advanced clinical T-stage, and higher Charlson-Deyo comorbidity score were all found to be unfavorably associated with OS (all P < 0.001) ( Table 2) . Primary disease located in the bladder wall, neck, and ureteric orifice were found to be favorably associated with survival (P < 0.001). Treatment at academic/ research programs was associated with favorable OS compared with comprehensive community (P < 0.001) and community cancer programs (P < 0.007). The HR for treatment with surgery versus bladder preservation was found to be dependent on time, with an initial HR of 1.27 (95% confidence interval [CI]: 1.11-1.44) favoring the CRT cohort and decreases by a factor of 0.85 (95% CI: 0.81-0.89) per year for surviving patients. The time-varying HR between surgery and CRT over time is depicted in Figure 3 .
Propensity-matched Analysis
Patients were propensity matched based on age at diagnosis, treatment facility type, Charlson-Deyo comorbidity index, primary disease site within the bladder, and clinical T-staging. The median follow-up time was 4.5 years for all patients. In the BPCRT cohort, 529 (52.8%) patients received single-agent chemotherapy, 391 (39.0%) patients received multiagent chemotherapy, and 82 (8.2%) patients received unspecified chemotherapy. The radiation therapy administered was exclusively external beam irradiation with photons. The median radiation dose received was 45 Gy in 25 fractions with an additional median boost of 19.8 Gy. The median total radiation dose was 64.8 Gy (10th to 90th percentile: 56.0 to 66.6 Gy), and the median total number of fractions in the CRT was 36 (10th to 90th percentile: 30 to 37). In the propensity-matched surgical cohort, 309 (30.8%) patients received chemotherapy, with 107 (10.7%) receiving neoadjuvant, 144 (14.4%) undergoing adjuvant, and 20 (2.0%) undergoing both neoadjuvant and adjuvant chemotherapy. Of those undergoing surgery, 854 (85.2%) patients were reported to have negative resection margins, 96 (9.6%) with involved margins, and 52 (5.2%) with unknown margin status. Following propensity matching, 1002 patients were assigned to each cohort, and the patient and disease characteristics were well matched with the exception of facility type, limited by the patient size in these subgroups ( Table 3) .
The Kaplan-Meier curves for the propensity-matched cohorts are displayed in Figure 2B and demonstrate similar median survival of 2.7 (95% CI: 2.4-3) and 3.0 years (95% CI: 2.6-3.4) for the BPCRT and surgery cohorts, respectively (P = 0.20). Likewise, the 4-year OS for the BPCRT and surgery cohorts were not statistically different at 39.1% and 42.6%, respectively (P = 0.15). Because of a violation of the PHs assumption, an interaction between treatment group and OS was fit for the propensity-matched groups, and a time-varying HR was produced. It demonstrated that the log HR of surgery versus BPCRT reduced by 0.16 (95% CI: 0.11-0.19) for every year increase in survival time (Fig. 3) .
DISCUSSION
The objective of this study was to compare survival outcomes in patients with clinically staged T2-T3N0M0 MIBC treated in the United States with either radical surgery or BPCRT. Our findings demonstrate similar median OS times in patients with MIBC treated with these 2 treatment strategies when propensity matched. These results suggest that not only is BPCRT feasible outside the clinical trial setting but also that the outcomes are comparable to those of radical cystectomy when patients are propensity matched. Our data additionally confirms BPCRT indicates bladder-preserving chemoradiation; NOS, not otherwise specified.
Bold values indicate significant P-values.
patient and disease characteristics previously reported to be negatively associated with survival, such as advanced age, advanced tumor stage, and poor baseline performance status. 5, 18 Our study is the first to suggest a demonstrable change in HR between receipt of radical surgery versus BPCRT. The finding of a time-varying HR between the 2 treatment groups may be accounted for in several ways. It may be that despite propensity matching, there still exists confounding factors leading to deaths unrelated to cancer in the BPCRT cohort, given the lack of granularity of the Charlson-Deyo score as a measure of performance status. 19 It is also possible that those patients treated with surgery initially had additional salvage treatment options unavailable to those in the BPCRT group. In addition, it has been documented that surgery-related deaths most commonly occur within the first 3 months following surgery, which could account for the initially low survival rate seen in this cohort. 20 Unfortunately, the NCDB does not provide detailed data regarding cause-specific death, and without such data, this finding is purely hypothesis generating at this time. Seisen et al 21 recently published a comparative study using the NCDB suggesting that long-term survivors treated with trimodality therapy were more likely to die than those treated with radical surgery. The time-varying HR from our data reconciles the outcomes of these 2 reports suggesting that at follow-up periods > 5 years, those patients in the surgery cohort who are still alive have a higher probability of surviving in the future. Our series also excluded those patients with T4 tumors, as these patients were generally excluded from bladderpreservation studies. Thus, the discrepancies in these 2 studies may also be due to better selection of patients suitable for bladder-preserving strategy.
The OS rates for both the BPCRT and surgical cohorts in this series were lower than those previously reported. The clinical trials utilizing BPCRT for patients with MIBC by the Radiation Therapy Oncology Group and British Columbia Cooperative Groups demonstrated 5-year OS rates between 35% and 83%. 5, 7, 8, [10] [11] [12] Similarly, large series investigating cystectomy outcomes with or without neoadjuvant chemotherapy have been reported to be 45% to 60%. 18, 22, 23 The lower survival rates in our series for both treatment cohorts is likely multifactorial. In our BPCRT cohort, ∼30% of patients had significant medical comorbidities, with Charlson-Deyo Scores of 1 or 2, which may have excluded them from participation in the cooperative group trials. In addition, treatment outside the strictly regulated clinical trial setting may allow patients to receive suboptimal doses/fields of radiation, chemotherapy, or both deviating from trial protocol.
Likewise, previously published cystectomy outcomes represent data from select high-volume centers, which has been associated with better cancer-specific survival and OS. 24 In our series, ∼30% of patients were not treated at academic/research programs or comprehensive cancer programs. In addition, while a survival benefit has been demonstrated on meta-analysis with the addition of neoadjuvant chemotherapy, only 30% of patients in our surgical cohort received systemic therapy, further accounting for inferior results. 18 Despite the lower survival rates presented in this series for both treatment strategies, our data represents actual outcomes in patients treated across the country.
Our analysis has several limitations. This study is a retrospective analysis of a national oncologic registry and carries limitations inherent in all retrospective studies. Namely, implied selection bias would be expected in such a study which seeks to retrospectively compare treatment with a curative surgery with a nonsurgical alternative. Given these considerations, we have taken every possible step to propensity match our cohorts with factors known to be associated with surgical in this patient population. The NCDB registry also lacks data regarding local control, treatment-related morbidity, chemotherapy agent, and specific cause of death. In addition, patients who may have received salvage radical cystectomy following CRT are not accurately captured and are not reported in our series. Moreover, detailed information regarding the chemotherapy agent, dose, and duration of treatment is not recorded by the NCDB. Furthermore, the NCDB does not capture toxicity data, and we believe that long-term toxicity from either treatment as well as patient-related outcomes could be crucial in the multidisciplinary decision making for patients with this disease. These factors should be taken into account for any future prospective studies.
Despite these limitations, this study contains a significant number of patients and directly compares the outcomes of patients with MIBC treated with definitive surgery versus BPCRT. Our results suggest that patients can be treated with the bladder-preserving approach outside the clinical trial setting 
